Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) on January 24 and set a price target of $150.00. The company’s shares closed last Thursday at $118.77, close to its 52-week low of $108.47.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zimmer Biomet Holdings with a $129.41 average price target, which is an 8.7% upside from current levels. In a report issued on February 8, Loop Capital Markets also maintained a Buy rating on the stock with a $140.00 price target.
Zimmer Biomet Holdings’ market cap is currently $24.81B and has a P/E ratio of 62.34.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.
Read More on ZBH:
- Shockwave Medical (SWAV) Gets a Buy Rating from Leerink Partners
- Robert W. Baird Thinks Honeywell International’s Stock is Going to Recover
- Robert W. Baird Keeps Their Buy Rating on L3Harris Technologies (LHX)
- Inspire Medical Systems (INSP) Receives a Buy from Leerink Partners
- Becton Dickinson (BDX) Gets a Hold Rating from Leerink Partners